Inclusion criteria:
Definitive diagnosis of MS with neurologist visit, based on the McDonald diagnostic criteria, at least 6 months have passed since the diagnosis.
Patients with relapsing-remitting MS or RRMS receiving first- and second-line MS disease therapy.
No relapse attacks one month before of the study.
Expression of willingness to participate in the study.
0 to 5 points based on expanded disability status scale.
َa fatigue intensity score equal to or higher than 4 according to the Fatigue severity scale
Having a feeling of chronic pain in at least one of the body organs and a score higher than 4 based on Numerical rating scale.
MS patients who take first and second line drugs (dimethyl fumarate, Resigen, Betaferon, Triflunomide, Fingolimido Cinomer).
Exclusion criteria:
Suffering from other diseases such as (chronic diseases, heart failure, glands, breathing, liver, kidney, skeletal-muscular) and mental diseases and severe depression.
Addiction to alcohol, drugs and psychedelics
History of allergy to saffron
Pregnancy and breastfeeding
The presence of severe infection and inflammation, varicose veins, active thrombosis, damage to organs such as fractures.
Motor disability score higher than 6
Getting any other serious diseases such as heart, liver and kidney diseases during treatment
Do heavy exercise daily
Any use of anti-inflammatory and antioxidant drugs as a supplement or Amantadine as an anti-fatigue drug
Unwillingness to participate in the study or continue the treatment process